Table 4

Predictors of hospitalisation for heart failure

UnivariateMultivariate
HR95% CIP valueHR95% CIP value
Age (per 1-year increase)1.030.97 to 1.100.279
Male1.320.72 to 2.400.372
NYHA class 3 or 41.170.66 to 2.090.595
DM1.150.63 to 2.090.650
Dyslipidaemia0.720.40 to 1.310.289
Hypertension1.930.82 to 4.560.133
CKD1.630.83 to 3.210.159
Atrial fibrillation1.700.94 to 3.060.077
PAD1.740.90 to 3.370.098
COPD1.380.71 to 2.670.338
BNP pg/mL (per 100 pg/mL increase)1.041.00 to 1.070.0381.061.01 to 1.110.025
STS score (per 1 U increase)1.031.00 to 1.060.022
Transapical approach1.520.80 to 2.890.199
TTE (pre-TAVI)
LAD, mm (per 1 mm increase)1.041.00 to 1.080.043
AVA, cm2 (per 0.1 cm2 decrease)0.960.78 to 1.170.672
MG, mm Hg (per 10 mm Hg decrease)1.681.08 to 2.610.020
SVi, mL/m2 (per 10 mL/m2 decrease)1.250.96 to 1.630.094
LVEF, % (per 10% decrease)1.231.02 to 1.500.033
Moderate-severe AR0.220.03 to 1.620.054
Moderate-severe MR2.971.47 to 5.990.0022.711.26 to 5.820.011
TTE (post-TAVI)
EOA, cm2 (per 0.1 cm2 decrease)1.060.99 to 1.150.111
MG, mm Hg (per 10 mm Hg decrease)2.891.11 to 7.460.029
SVi, mL/m2 (per 10 mL/m2 decrease)1.471.16 to 1.870.0011.351.03 to 1.760.028
LVEF, % (per 10% decrease)1.301.05 to 1.610.015
Moderate-severe PVL1.600.22 to 11.60.642
Moderate-severe MR2.401.08 to 5.380.033
  • AR, aortic regurgitation; AVA, aortic valve area; BNP, brain natriuretic peptide; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; EOA, effective orifice area; LAD, left atrial diameter; LVEF, left ventricular ejection fraction; MG, mean pressure gradient; MR, mitral regurgitation; NYHA, New York Heart Association; PAD, peripheral artery disease; PVL, paravalvular leakage; STS, Society of Thoracic Surgeons' risk model; SVi, stroke volume index; TAVI, transcatheter aortic valve implantation; TTE, transthoracic echocardiography.